Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.

ABSTRACT:

Aim

Maintenance treatment in ulcerative colitis should be as convenient as possible, to increase the chance of compliance. MMX mesalazine is a once-daily, high-strength (1.2 g/tablet) formulation of 5-aminosalicylic acid. This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis.

Methods

This multicentre, randomised, open-label trial enrolled patients with strictly defined clinical and endoscopic remission, immediately following an episode of mild to moderate ulcerative colitis. Patients were randomised to MMX mesalazine 2.4 g/day as a single (2x1.2 g tablet) or divided dose (1x1.2 g tablet twice daily) for 12 months.

Results

174 patients (37.9%; safety population n = 459) experi

SUBMITTER: Kamm MA 

PROVIDER: S-EPMC2564831 | biostudies-literature | 2008 Jul

REPOSITORIES: biostudies-literature